Inhibrx reports Q2 EPS ($1.08), consensus ($1.03)

Reports Q2 revenue $30,000. As of June 30 Inhibrx had cash and cash equivalents of $192.5M, compared to $273.9M as of December 31, 2022. The increase in cash outflow during the second quarter of 2023 was a result of the timing of payments made to the Company’s contract development and manufacturing organizations, or CDMOs, related to development and manufacturing costs supporting our clinical and preclinical candidates.